168 related articles for article (PubMed ID: 23171003)
1. Association of genetic variations in GNB1 with response to peginterferon plus ribavirin therapy for chronic hepatitis C in a Chinese population in Taiwan.
Lim YP; Tsai FJ; Liao WL; Tien N; Hung DZ; Peng CY; Wan L
BMC Gastroenterol; 2012 Nov; 12():167. PubMed ID: 23171003
[TBL] [Abstract][Full Text] [Related]
2. The impact of polymorphisms in STAT6 on treatment outcome in HCV infected Taiwanese Chinese.
Lim YP; Hsu YA; Tsai KH; Tsai FJ; Peng CY; Liao WL; Hung DZ; Tien N; Lin CY; Wan L
BMC Immunol; 2013 May; 14():21. PubMed ID: 23651608
[TBL] [Abstract][Full Text] [Related]
3. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
[TBL] [Abstract][Full Text] [Related]
4. Genetic variation in NOS2A is associated with a sustained virological response to peginterferon plus ribavirin therapy for chronic hepatitis C in Taiwanese Chinese.
Lim YP; Peng CY; Liao WL; Hung DZ; Tien N; Chen CY; Chang SY; Chang CY; Tsai FJ; Wan L
J Med Virol; 2013 Jul; 85(7):1206-14. PubMed ID: 23918539
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Hartwell D; Jones J; Baxter L; Shepherd J
Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
[TBL] [Abstract][Full Text] [Related]
6. Association of MRC-1 and IL-28B with the treatment outcome of hepatitis C: a case control study.
Peng CY; Chen TH; Lim YP; Tsai FJ; Lin WY; Liao WL; Wan L
BMC Gastroenterol; 2014 Jun; 14():113. PubMed ID: 24969847
[TBL] [Abstract][Full Text] [Related]
7. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients.
Yu ML; Huang CF; Huang JF; Chang NC; Yang JF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Li YN; Wu MS; Dai CY; Juo SH; Chuang WL
Hepatology; 2011 Jan; 53(1):7-13. PubMed ID: 21254157
[TBL] [Abstract][Full Text] [Related]
8. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
[TBL] [Abstract][Full Text] [Related]
9. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
Rallón NI; Soriano V; Naggie S; Restrepo C; Goldstein D; Vispo E; McHutchison J; Benito JM
AIDS; 2011 May; 25(8):1025-33. PubMed ID: 21505315
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
11. IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population.
Martínez-Gómez LE; Chávez-Tapia NC; Burguete-García AI; Aguilar-Olivos N; Madrid-Marina V; Román-Bahena M; Orbe-Orihuela C; Misael U; Méndez-Sánchez N
Ann Hepatol; 2012; 11(6):876-81. PubMed ID: 23109451
[TBL] [Abstract][Full Text] [Related]
12. Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.
Domagalski K; Pawłowska M; Tretyn A; Halota W; Pilarczyk M; Smukalska E; Linkowska K; Grzybowski T
Eur J Clin Microbiol Infect Dis; 2013 Jun; 32(6):745-54. PubMed ID: 23314745
[TBL] [Abstract][Full Text] [Related]
13. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.
Jacobson I; Zeuzem S; Flisiak R; Knysz B; Lueth S; Zarebska-Michaluk D; Janczewska E; Ferenci P; Diago M; Zignego AL; Safadi R; Baruch Y; Abdurakhmanov D; Shafran S; Thabut D; Bruck R; Gadano A; Thompson AJ; Kopit J; McPhee F; Michener T; Hughes EA; Yin PD; Noviello S
World J Gastroenterol; 2016 Mar; 22(12):3418-31. PubMed ID: 27022224
[TBL] [Abstract][Full Text] [Related]
14. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
[TBL] [Abstract][Full Text] [Related]
15. Interferon-λ-related genes and therapeutic response in Chinese hepatitis C patients.
Zhang YY; Chen HB; Xu Y; Huang P; Wang J; Zhang Y; Yu RB; Su J
World J Gastroenterol; 2015 Apr; 21(13):4006-13. PubMed ID: 25852288
[TBL] [Abstract][Full Text] [Related]
16. No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients.
Heo NY; Lim YS; Lee W; Oh M; An J; Lee D; Shim JH; Kim KM; Lee HC; Lee YS; Suh DJ
Clin Mol Hepatol; 2014 Jun; 20(2):177-84. PubMed ID: 25032184
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.
Liu CH; Liang CC; Liu CJ; Tseng TC; Lin CL; Yang SS; Su TH; Hsu SJ; Lin JW; Chen JH; Chen PJ; Chen DS; Kao JH
Antivir Ther; 2012; 17(3):477-84. PubMed ID: 22301466
[TBL] [Abstract][Full Text] [Related]
18. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.
Huang CF; Yang JF; Huang JF; Dai CY; Chiu CF; Hou NJ; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
J Gastroenterol Hepatol; 2010 Apr; 25(4):758-65. PubMed ID: 20492331
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of
Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
[TBL] [Abstract][Full Text] [Related]
20. Retreatment with peginterferon α-2a + ribavirin in patients who failed previous peginterferon α-2b + ribavirin combination therapy.
Ueda T; Tsuchiya K; Hashimoto S; Inoue T; Enomoto N; Inao M; Tanaka A; Kaito M; Imazeki F; Nishiguchi S; Mochida S; Yokosuka O; Yatsuhashi H; Izumi N; Kudo M;
Dig Dis; 2012; 30(6):554-60. PubMed ID: 23258094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
